⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
KYMR News
Kymera Therapeutics, Inc. Common Stock
Kymera Therapeutics to Announce KT-621 BroADen Phase 1b Atopic Dermatitis Trial Results on December 8, 2025
globenewswire.com
KYMR
Aluminum Metal Powder Market worth $2.64 billion by 2030 - Exclusive Report by MarketsandMarkets™
prnewswire.com
AMGGY
KYMR
NVTS
VALMT
Kymera Therapeutics Announces First Patient Dosed in BROADEN2 Phase 2b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader
globenewswire.com
KYMR
Kymera Therapeutics to Participate in Upcoming December Investor Conferences
globenewswire.com
KYMR
Kymera Therapeutics Announces Third Quarter 2025 Financial Results and Provides a Business Update
globenewswire.com
KYMR
Kymera Therapeutics to Participate in Upcoming November Investor Conferences
globenewswire.com
KYMR
Kymera Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025
globenewswire.com
KYMR
Kymera Therapeutics Presents New Preclinical Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at the American College of Rheumatology Annual Meeting
globenewswire.com
KYMR